Want to see MKKGY full AI Analyst Report?
MKKGY Stock Chart & Stats
$29.80
--
Market closed
$29.80
--
Day’s Range― - ―
52-Week Range$23.82 - $33.76
Previous CloseN/A
VolumeN/A
Average Volume (3M)19.41K
Market Cap
$67.65B
Enterprise Value$64.70K
Total Cash (Recent Filing)$3.77B
Total Debt (Recent Filing)$12.05B
Price to Earnings (P/E)23.2
Beta0.55
Next Earnings
Aug 06, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend Yield1.67%
Share Statistics
EPS (TTM)1.15
Shares Outstanding646,211,240
10 Day Avg. Volume0
30 Day Avg. Volume19,407
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)1.86
Price to Sales (P/S)2.62
P/FCF Ratio23.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.84
Revenue Forecast (FY)$24.26B
Bulls Say, Bears Say
Bulls Say
Life Science MomentumDurable demand for consumables and bioprocessing (Process Solutions +16%) and book-to-bill >1 indicate recurring, sticky revenue from lab and biomanufacturing customers. This supports midterm organic growth potential and reduces reliance on cyclical end markets.
Cash Generation & DeleveragingStrong operating cash flow and declining net debt demonstrate healthy free cash generation and balance-sheet flexibility. This underpins capacity for R&D, targeted M&A, dividends, and cushioning against cyclical shocks over the next several quarters.
Upgraded Guidance & Strategic M&AManagement raised full-year targets and is executing accretive M&A (JSR) to expand platform capabilities. Clear strategy to prioritize high-growth workflows and disciplined deals supports sustainable revenue mix improvement and longer-term margin expansion.
Bears Say
Healthcare Franchise PressureGeneric erosion of key drugs like Mavenclad drives persistent volume and pricing pressure in Healthcare, reducing segment margins and requiring increased launch and marketing investment. This structural headwind can depress midterm healthcare profitability and growth.
Weakening Top-Line TrendA deteriorating top-line trend and negative TTM growth signal lower demand or portfolio impacts that reduce operating leverage. Even with solid margins, continued revenue weakness constrains sustainable earnings growth and increases reliance on cost or nonrecurring items.
Electronics Profitability VolatilityReported electronics margin improvements were aided by nonrecurring gains and face significant FX and divestment-related headwinds. This raises risk that recent profitability is ephemeral, making segment earnings and group margin less predictable over the medium term.
MKKGY FAQ
What was Merck KGaA Sponsored ADR’s price range in the past 12 months?
Merck KGaA Sponsored ADR lowest stock price was $23.82 and its highest was $33.76 in the past 12 months.
What is Merck KGaA Sponsored ADR’s market cap?
Merck KGaA Sponsored ADR’s market cap is $67.65B.
When is Merck KGaA Sponsored ADR’s upcoming earnings report date?
Merck KGaA Sponsored ADR’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Merck KGaA Sponsored ADR’s earnings last quarter?
Merck KGaA Sponsored ADR released its earnings results on May 13, 2026. The company reported $0.494 earnings per share for the quarter, beating the consensus estimate of $0.456 by $0.038.
Is Merck KGaA Sponsored ADR overvalued?
According to Wall Street analysts Merck KGaA Sponsored ADR’s price is currently Overvalued.
Does Merck KGaA Sponsored ADR pay dividends?
Merck KGaA Sponsored ADR pays a Annually dividend of $0.515 which represents an annual dividend yield of 1.67%. See more information on Merck KGaA Sponsored ADR dividends here
What is Merck KGaA Sponsored ADR’s EPS estimate?
Merck KGaA Sponsored ADR’s EPS estimate is 0.46.
How many shares outstanding does Merck KGaA Sponsored ADR have?
Merck KGaA Sponsored ADR has 646,211,240 shares outstanding.
What happened to Merck KGaA Sponsored ADR’s price movement after its last earnings report?
Merck KGaA Sponsored ADR reported an EPS of $0.494 in its last earnings report, beating expectations of $0.456. Following the earnings report the stock price went up 6.968%.
Which hedge fund is a major shareholder of Merck KGaA Sponsored ADR?
Currently, no hedge funds are holding shares in MKKGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.59%
12-Months-Change
Fundamentals
Return on Equity
1.67%
Trailing 12-Months
Asset Growth
14.65%
Trailing 12-Months
Company Description
Merck KGaA Sponsored ADR
Merck KGaA is a leading German science and technology enterprise. Its business operations are strategically organized into three core divisions: Life Science, Healthcare, and Electronics. The Life Science segment provides an extensive portfolio of tools, chemicals, and equipment essential for academic research laboratories, biotech firms, pharmaceutical manufacturers, and the broader industrial sector. This division also furnishes drug developers with specialized process development expertise and advanced technologies, such as continuous bioprocessing, alongside a variety of testing kits, reagents, and associated services. Furthermore, it delivers analytical solutions for environmental monitoring (air, water, and soil) and products designed to evaluate nutritional content and detect quality deviations. The Healthcare segment focuses on the discovery, development, manufacturing, and commercialization of prescription drugs and biopharmaceuticals. Its therapeutic areas encompass oncology, neurology and immunology, fertility, endocrinology, cardiovascular conditions, diabetes, thyroid disorders, and multiple sclerosis. This segment also markets general medicines and integrates medical technology, including injection devices and disease monitoring software. The Electronics segment supplies critical materials to the semiconductor and display industries. It also specializes in surface design solutions, offering comprehensive delivery systems, services, and innovative surface products, which include cosmetic ingredients, effect pigments, and various functional applications. Beyond its internal operations, Merck KGaA actively pursues strategic collaborations. This includes in-licensing agreements, such as with Debiopharm International SA for drug candidates targeting head and neck cancer; with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for treatments against metastatic colorectal cancer; and with Abbisko Therapeutics Co. Ltd. for therapies for tenosynovial giant cell tumor. The company also holds a license and collaboration agreement dedicated to identifying two targeted protein degraders for vital oncogenic proteins. Established in 1668, Merck KGaA boasts a long and distinguished history and is headquartered in Darmstadt, Germany. The company functions as a subsidiary under the umbrella of E. Merck KG.
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―
Haleon PLC Sponsored ADR
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors